STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

MADRID — The combination of an experimental drug from Tango Therapeutics and Revolution Medicines’ Rasonque led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed.  The responses were also durable: 88% of the patients were still alive without tumor progression when assessed at nine months.  The new data bolster the theory that patients with pancreatic cancer can derive more benefit from combinations of targeted d...